Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Sophia T. Huesmann
Observed names:
Huesmann, Sophia T.,
Sophia Huesmann
Institution:
University Hospital Ulm
Observed institutions:
Universität Ulm,
University Hospital Ulm
OpenAlex ID:
A5000387178
The SURVIVE study: Liquid biopsy guided surveillance after intermediate- to high-risk early breast cancer.
2024
·
Kerstin Pfister
, Sophia Huesmann
, et al.
·
Journal of Clinical Oncology
·
15
Abstract 3403: Multiomic, plasma-only circulating tumor DNA (ctDNA) assay identifies breast cancer patients with minimal residual disease (MRD) and predicts distant recurrence
2022
·
Wolfgang Janni
, Jens Huober
, et al.
·
Cancer Research
·
14
Novel Antibody-Drug-Conjugates in Routine Clinical Practice for the Treatment of Metastatic Breast Cancer: Adherence, Efficacy and Tolerability – Real-World Data from German Breast Centers
2024
·
Henning Schäffler
, Dorothee Jakob
, et al.
·
Geburtshilfe und Frauenheilkunde
·
10
PDF
The SURVIVE study (NCT05658172): Bringing breast cancer aftercare to the 21stcentury: Study protocol of a Phase III clinical trial comparing liquid biopsy guided vs. Standard of care surveillance for intermediate to high-risk breast cancer survivors
2025
·
Tatjana Braun
, Sophia Huesmann
, et al.
·
PLoS ONE
·
7
PDF
Study Protocol of SURVIVE HERoes (NCT06643585): Trastuzumab Deruxtecan for molecular relapse in HER2+/ Low early breast cancer with ctDNA positivity after primary therapy
2025
·
Kerstin Pfister
, Thomas W. P. Friedl
, et al.
·
PLoS ONE
·
5
PDF
Abstract PO4-19-01: The SURVIVE-HERoes trial – a secondary adjuvant treatment intervention study with trastuzumab-deruxtecan in patients with HER2 positive/HER2 low early breast cancer and a molecular relapse, based on a positive ctDNA result
2024
·
Sophia Huesmann
, Franziska Mergel
, et al.
·
Cancer Research
·
5
Abstract PO1-20-05: SURVIVE study – a multicenter, randomized, controlled phase 3 superiority trial, evaluating liquid biopsy guided intensified follow-up surveillance in women with intermediate-to high-risk early breast cancer
2024
·
Franziska Mergel
, Sophia Huesmann
, et al.
·
Cancer Research
·
4
Will Minimal Residual Disease Monitoring Be Part of Routine Surveillance?
2025
·
Kerstin Pfister
, Henning Schäffler
, et al.
·
Oncology Research and Treatment
·
3
Nachsorge beim Mammakarzinom – endlich Bewegung?
2024
·
Sophia T. Huesmann
, Sabine Heublein
, et al.
·
Die Gynäkologie
·
2
Abstract P2-01-07: Detection of early-stage breast cancer recurrence using a personalised liquid biopsy-based sequencing approach
2022
·
Wolfgang Janni
, Jens Huober
, et al.
·
Cancer Research
·
2
The SURVIVE study: Standard surveillance vs. intensified liquid biopsy-based surveillance in early breast cancer survivors.
2025
·
Henning Schäffler
, Sophia Huesmann
, et al.
·
Journal of Clinical Oncology
·
1
Interception of molecular relapse in breast cancer: The SURVIVE HERoes study (NCT06643585).
2026
·
Wolfgang Janni
, Thomas W. P. Friedl
, et al.
·
Journal of Clinical Oncology
The SURVIVE study: Re-evaluating follow-up in early breast cancer.
2026
·
Sophia T. Huesmann
, Thomas W. P. Friedl
, et al.
·
Journal of Clinical Oncology
Die Nachsorge beim Mammakarzinom
2026
·
Sophia T. Huesmann
, Brigitte Rack
, et al.
·
MMW - Fortschritte der Medizin
Innovationen in der Nachsorge
2026
·
Kerstin Pfister
, Kristina Veselinovic
, et al.
·
Die Gynäkologie
Von der Routine zur Präzisionsmedizin – die Nachsorge beim frühen Mammakarzinom auf dem Prüfstand
2025
·
Sophia T. Huesmann
, Henning Schäffler
, et al.
·
Die Gynäkologie
PDF
Neue Antikörper-Wirkstoff-Konjugate in der klinischen Praxis zur Behandlung des metastatischen Brustkrebses: Therapie-Adhärenz, Wirksamkeit und Verträglichkeit – Real-World-Daten aus deutschen Brustkrebszentren
2025
·
Henning Schäffler
, Dorothee Jakob
, et al.
·
Senologie - Zeitschrift für Mammadiagnostik und -therapie
The SURVIVE HERoes study: Targeting molecular relapse in breast cancer—A secondary adjuvant intervention study of trastuzumab deruxtecan versus SOC treatment in patients with HER2-positive or HER2-low early breast cancer and ctDNA positivity after primary therapy.
2025
·
Kerstin Pfister
, Thomas W. P. Friedl
, et al.
·
Journal of Clinical Oncology
PDF
The survive study - Liquid biopsy guided surveillance in intermediate- to high-risk early breast cancer
2024
·
Christodoulos Pipinikas
, Kerstin Pfister
, et al.
·
The Journal of Liquid Biopsy
PDF
Show more works
View as search
Works count:
20
Citation count:
68
H-index:
5
I10-index:
3
Year
Topic
Type
